Last updated: 2026-09-09 00:35:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Co-Diagnostics, Inc. (CODX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1,12, with a market capitalisation of $8,10M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,94 to $46,50. This page covers its latest market performance, valuation, price trends and company information.
$8,10M | |
$1,14 | |
$929,70 | |
$0,94 | |
$1,16 | |
78,83K | |
449,42K | |
-- | |
$46,50 | |
$0,94 | |
-- | |
-- |
Co-Diagnostics, Inc. (CODX) last closed at $1,16 as of 2026-09-08 23:56:00, unchanged from the previous close of $1,16.
During the latest regular trading session, CODX traded between $0,94 and $929,70, with a volume of 78,83K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Co-Diagnostics, Inc. (CODX) moved from $1,26 to $1,12, representing a decline of 11,11% ($0,14).
The stock traded between $1,12 and $1,42 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 110,43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,4%
CODX is currently trading at $1,12, placing it 0,4% of the way from its 52-week low of $0,94 to its 52-week high of $46,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 115 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Co-Diagnostics, Inc. (CODX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.